Ticker
ABBV

Price
157.06
Stock movement down
-1.20 (-0.76%)
Company name
AbbVie Inc
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Market cap
277.08B
Ent value
389.39B
Price/Sales
4.77
Price/Book
16.03
Div yield
3.95%
Div growth
10.52%
Growth years
9
FCF payout
41.42%
Trailing P/E
23.41
Forward P/E
14.12
PEG
2.83
EPS growth
14.98%
1 year return
11.27%
3 year return
10.66%
5 year return
14.12%
10 year return
11.42%
Last updated: 2024-05-24

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

BUSINESS INSIGHT

Revenues per Product Category ($M)

Loading...
Company comments

AbbVie was created through a spinoff from Abbott Laboratories in 2013

Humira is the world’s #1 global pharmaceutical product by a large margin

AbbVie acquired Allergan, the maker of Botox in 2020, hence the huge jump in revenues and the change in the segment classifications

Geographic Revenues ($M)

Loading...

iO Charts is a Seeking Alpha partner

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share6.20
Dividend yield3.95%
Payout frequencyQuarterly
Maximum yield7.32%
Average yield4.59%
Minimum yield3.22%
Discount to avg yield-16.29%
Upside potential-14.01%
Yield as % of max yield53.94%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield3.95%
Current yield distribution72.46%
Yield at 100% (Min)3.22%
Yield at 90%3.68%
Yield at 80%3.84%
Yield at 50% (Median)4.46%
Yield at 20%5.30%
Yield at 10%5.77%
Yield at 0% (Max)7.32%

Dividend per share

Loading...
Dividend per share data
Years of growth9 years
CCC statusDividend Challenger
Dividend per share6.20
Payout frequencyQuarterly
Ex-div date12 Apr 2024
EPS (TTM)6.66
EPS (1y forward)11.12
EPS growth (5y)14.98%
EPS growth (5y forward)8.27%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
ABBVS&P500
DGR MR4.73%-16.32%
DGR TTM4.84%4.05%
DGR 3 years7.84%5.24%
DGR 5 years10.52%5.40%
DGR 10 years-7.07%
DGR 15 years-6.12%
Time since last change announced213 days
EPS growth (5y)14.98%
EPS growth (5y forward)8.27%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM84.85%41.42%
Average--
Forward55.76%-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E23.41
Price to OCF11.11
Price to FCF11.43
Price to EBITDA11.99
EV to EBITDA16.85

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales4.77
Price to Book16.03
EV to Sales6.71

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count1.76B
EPS (TTM)6.66
FCF per share (TTM)13.64

Income statement

Loading...
Income statement data
Revenue (TTM)58.05B
Gross profit (TTM)40.64B
Operating income (TTM)18.36B
Net income (TTM)11.84B
EPS (TTM)6.66
EPS (1y forward)11.12

Margins

Loading...
Margins data
Gross margin (TTM)70.00%
Operating margin (TTM)31.63%
Profit margin (TTM)20.39%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash9.20B
Net receivables11.25B
Total current assets28.46B
Goodwill32.16B
Intangible assets67.44B
Property, plant and equipment0.00
Total assets138.81B
Accounts payable25.40B
Short/Current long term debt63.27B
Total current liabilities29.54B
Total liabilities121.52B
Shareholder's equity17.29B
Net tangible assets-82.34B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)24.94B
Capital expenditures (TTM)695.00M
Free cash flow (TTM)24.25B
Dividends paid (TTM)10.04B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity68.47%
Return on Assets8.53%
Return on Invested Capital14.69%
Cash Return on Invested Capital30.10%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open158.36
Daily high158.78
Daily low156.36
Daily Volume3.69M
All-time high182.10
1y analyst estimate163.87
Beta0.59
EPS (TTM)6.66
Dividend per share6.20
Ex-div date12 Apr 2024
Next earnings date25 Jul 2024

Downside potential

Loading...
Downside potential data
ABBVS&P500
Current price drop from All-time high-13.75%-0.36%
Highest price drop-48.88%-56.47%
Date of highest drop15 Aug 20199 Mar 2009
Avg drop from high-14.02%-11.31%
Avg time to new high18 days13 days
Max time to new high975 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ABBV (AbbVie Inc) company logo
Marketcap
277.08B
Marketcap category
Large-cap
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Employees
50000
SEC filings
CEO
Richard Gonzalez
Country
USA
City
North Chicago
Stock type
Common stock
CCC status
Dividend Challenger
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...